via National Human Genome Research Institute
Researchers from the University of Sheffield have discovered a new gene therapy pathway that has the potential to protect us against serious life-limiting diseases such as cancer and dementia
Researchers from the University of Sheffield have discovered a new gene therapy pathway that has uncovered an important regulatory mechanism to keep our genome healthy. This pathway has the potential to protect us against serious life-limiting diseases such as cancer and dementia.
Cancer and neurodegeneration are two major health challenges currently affecting the population, and they constitute two sides of the same coin – one is caused by uncontrolled cell proliferation due to genome damage, and the other is caused by excessive genome damage that causes cell death. This new pathway impacts both and offers new therapeutic opportunities to help the fight against disease.
Published in Nature Communications, the research found that when cells in our body read DNA to build proteins, they often make mistakes that can damage our genome, causing disease such as cancer and dementia. However, by investigating how cells fix damage in the DNA to keep us healthy, scientists have discovered the benefits of three proteins working together as a team. The three proteins, called USP11, KEAP1 and SETX, receive instructions from their coach to direct their function in space and time with remarkable harmony, to keep our DNA healthy.
By understanding how cells protect themselves from these mistakes and thus preventing diseases, scientists are able to modify the behaviour of these proteins to promote the health and wellbeing of people.
Findings from this study will enable scientists to develop diagnostic tests and drugs to target one or more of the proteins in the pathway for the early detection and treatment of certain types of cancer and neurological disease. Developing new drugs to regulate the level of one or more of these proteins is expected to offer new treatments for cancer and dementia.
The findings are important and significant, this is because we are now at the stage where we could make drugs to control this modification. This would be useful in killing cells, which is what we do when we treat elderly people for cancer. The other application would be to reduce the level of genome damage, which could be beneficial for other ageing associated disorders like dementia.
Original Article: New gene therapy pathway could protect us from cancer and dementia
More from: University of Sheffield
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Gene therapy pathway
- Gene therapy restores vision after stroke: Studyon October 9, 2021 at 11:43 pm
Most strokes happen when an artery in the brain becomes blocked. Blood flow to the neural tissue stops, and those tissues typically die. Because of th..
- Gene therapy restores lost vision after stroke: Studyon October 9, 2021 at 11:45 am
Neurons don't regenerate. The brain can sometimes remap its neural pathways enough to restore some visual function after a stroke, but that process is slow, it's inefficient, and for some patients, it ...
- Restoring visual function after stroke with gene therapyon October 3, 2021 at 9:23 am
Most strokes happen when an artery in the brain becomes blocked. Blood flow to the neural tissue stops, and those tissues typically die. Because of the locations of the major arteries in the brain, ...
- Gene therapy can restore vision after strokeon October 2, 2021 at 10:28 am
Vision loss can be a side effect from stroke. Neurons don't regenerate, and stem cell therapy is costly, difficult, and chancy. Researchers have figured out a way to use gene therapy to recover lost ...
- Towards a Gene Therapy for Heart Regenerationon September 22, 2021 at 3:21 pm
The work has been reported in Science Translational Medicine, and could bring a gene therapy for heart failure closer to use in patients. "One of the interests of my lab is to develop ways to heal ...
Go deeper with Google Headlines on:
Gene therapy pathway
Go deeper with Bing News on:
- GenSight Biologics Announces FDA Grant of Fast Track Designation for Optogenetic Therapy GS030 as Treatment for Retinitis Pigmentosaon October 11, 2021 at 10:30 pm
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative ...
- Bone Therapeutics appoints Scientific Advisory Board for iMSC cell and gene therapy platform developmenton October 11, 2021 at 10:05 pm
BONE THERAPEUTICS(Euronext Brussels and Paris: BOTHE), the cell therapy company addressing unmet medical needs in orthopedics and other diseases, today announces it has appointed key experts to a ...
- Sarepta's Duchenne Gene Therapy Shows Sustained Functional Improvementson October 11, 2021 at 12:25 pm
Sarepta Therapeutics Inc (NASDAQ: SRPT) shared new analyses and functional data from its SRP-9001 development program and the details of Study SRP-9001-301 (EMBARK) Phase 3 trial of SRP-9001 for ...
- Regenxbio Reveals Interim Data From Diabetic Retinopathy Gene Therapy Trialon October 11, 2021 at 12:25 pm
Regenxbio Inc (NASDAQ:RGNX) announced initial data from the Phase 2 ALTITUDE trial of RGX-314 for diabetic retinopathy (DR) without center-involved diabetic macular edema (CI-DME) ...
- Sarepta outlines final push for Duchenne gene therapyon October 11, 2021 at 11:33 am
The biotech still believes a speedy approval filing for the closely watched treatment is possible, but expects to have to wait for the results of the recently launched Phase 3 trial, CEO Doug Ingram ...